These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 34231532)

  • 41. Intravitreal bevacizumab versus laser treatment in type 1 retinopathy of prematurity: report on fluorescein angiographic findings.
    Lepore D; Quinn GE; Molle F; Baldascino A; Orazi L; Sammartino M; Purcaro V; Giannantonio C; Papacci P; Romagnoli C
    Ophthalmology; 2014 Nov; 121(11):2212-9. PubMed ID: 25001158
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Reactivation of retinopathy of prematurity after ranibizumab treatment.
    Wong RK; Hubschman S; Tsui I
    Retina; 2015 Apr; 35(4):675-80. PubMed ID: 25768252
    [TBL] [Abstract][Full Text] [Related]  

  • 43. One-year refractive outcomes after intravitreal bevacizumab versus laser photocoagulation for retinopathy of prematurity.
    Kıran Yenice E; Petriçli İS; Kara C
    Int Ophthalmol; 2023 Jul; 43(7):2197-2202. PubMed ID: 36522564
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Chronic Vascular Arrest as a Predictor of Bevacizumab Treatment Failure in Retinopathy of Prematurity.
    Toy BC; Schachar IH; Tan GS; Moshfeghi DM
    Ophthalmology; 2016 Oct; 123(10):2166-75. PubMed ID: 27506484
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Combination of laser photocoagulation and intravitreal bevacizumab (Avastin) for aggressive zone I retinopathy of prematurity.
    Chung EJ; Kim JH; Ahn HS; Koh HJ
    Graefes Arch Clin Exp Ophthalmol; 2007 Nov; 245(11):1727-30. PubMed ID: 17690897
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Short-term retinal detachment risk after treatment of type 1 retinopathy of prematurity with laser photocoagulation versus intravitreal bevacizumab.
    Barry GP; Tauber KA; Fisher M; Greenberg S; Zobal-Ratner J; Binenbaum G
    J AAPOS; 2019 Oct; 23(5):260.e1-260.e4. PubMed ID: 31513902
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Current and future trends in treatment of severe retinopathy of prematurity.
    Wallace DK; Wu KY
    Clin Perinatol; 2013 Jun; 40(2):297-310. PubMed ID: 23719311
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Morphological outcome and indication for laser following intravitreal bevacizumab monotherapy for posterior retinopathy of prematurity.
    Sindal MD; Nagesha CK; Yadav D; Fazal R
    Lasers Med Sci; 2022 Jul; 37(5):2501-2508. PubMed ID: 35106690
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Combined Vitrectomy and Anti-VEGF Treatment for Stage 4 Retinopathy of Prematurity With Extensive Neovascular Proliferation.
    Chandra P; Kumawat D; Agarwal D; Chawla R
    J Pediatr Ophthalmol Strabismus; 2020 Jan; 57(1):61-66. PubMed ID: 31972043
    [TBL] [Abstract][Full Text] [Related]  

  • 50. RATES AND RISK FACTORS FOR RECURRENCE OF RETINOPATHY OF PREMATURITY AFTER LASER OR INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR MONOTHERAPY.
    Ling KP; Liao PJ; Wang NK; Chao AN; Chen KJ; Chen TL; Hwang YS; Lai CC; Wu WC
    Retina; 2020 Sep; 40(9):1793-1803. PubMed ID: 31800460
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Bilateral Vitreous Hemorrhage Following Bilateral Intravitreal Injections of Bevacizumab in an Infant With Retinopathy of Prematurity.
    Theophanous C; Schechet S; Rodriguez SH; Blair M
    Ophthalmic Surg Lasers Imaging Retina; 2018 Nov; 49(11):893-896. PubMed ID: 30457649
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Practice Patterns and Outcomes of Intravitreal Anti-VEGF Injection for Retinopathy of Prematurity: An International Multicenter Study.
    Patel NA; Acaba-Berrocal LA; Hoyek S; Fan KC; Martinez-Castellanos MA; Baumal CR; Harper CA; Berrocal AM;
    Ophthalmology; 2022 Dec; 129(12):1380-1388. PubMed ID: 35863512
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Serious adverse events and visual outcomes of rescue therapy using adjunct bevacizumab to laser and surgery for retinopathy of prematurity. The Indian Twin Cities Retinopathy of Prematurity Screening database Report number 5.
    Jalali S; Balakrishnan D; Zeynalova Z; Padhi TR; Rani PK
    Arch Dis Child Fetal Neonatal Ed; 2013 Jul; 98(4):F327-33. PubMed ID: 23269586
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Intravitreal injection of bevacizumab for retinopathy of prematurity.
    Kuniyoshi K; Sugioka K; Sakuramoto H; Kusaka S; Wada N; Shimomura Y
    Jpn J Ophthalmol; 2014 May; 58(3):237-43. PubMed ID: 24566819
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Longitudinal Change of Refractive Error in Retinopathy of Prematurity Treated With Intravitreal Bevacizumab or Laser Photocoagulation.
    Wiecek E; Akula JD; Vanderveen DK; Mantagos IS; Wu C; Curran AL; De Bruyn H; Peterson B; Fulton AB
    Am J Ophthalmol; 2022 Aug; 240():252-259. PubMed ID: 35367438
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Treated cases of retinopathy of prematurity in Germany : 5-year data from the Retina.net ROP registry].
    Walz JM; Bemme S; Reichl S; Akman S; Breuß H; Süsskind D; Glitz B; Müller VC; Wagenfeld L; Gabel-Pfisterer A; Aisenbrey S; Engelmann K; Koutsonas A; Krohne TU; Stahl A;
    Ophthalmologe; 2018 Jun; 115(6):476-488. PubMed ID: 29637302
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Long-term effects of anti-VEGF therapy for retinopathy of prematurity].
    Krohne TU; Müller A; Larsen PP; Holz FG
    Ophthalmologe; 2018 Jun; 115(6):464-468. PubMed ID: 29654389
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Combined intravitreal bevacizumab injection and zone I sparing laser photocoagulation in patients with zone I retinopathy of prematurity.
    Kim J; Kim SJ; Chang YS; Park WS
    Retina; 2014 Jan; 34(1):77-82. PubMed ID: 23807184
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Refractive outcomes following the treatment of retinopathy of prematurity in the anti-VEGF era: a literature review.
    Abri Aghdam K; Khadamy J; Falavarjani KG; Tsui I
    J AAPOS; 2016 Dec; 20(6):539-540.e3. PubMed ID: 27810419
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trial.
    Stahl A; Lepore D; Fielder A; Fleck B; Reynolds JD; Chiang MF; Li J; Liew M; Maier R; Zhu Q; Marlow N
    Lancet; 2019 Oct; 394(10208):1551-1559. PubMed ID: 31522845
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.